Viral hepatitis screening guideline before biological drug use in rheumatic patients
Biological drugs (tumor necrosis factor inhibitors, rituximab, tocilizumab, abatacept, and tofacitinib) are important treatment alternatives in rheumatology, particularly for resistant patients. However, they may cause hepatitis B virus (HBV) and hepatitis C virus (HCV) reactivation; for instance, HBV reactivation may occur in a patient who is an inactive hepatitis B surface antigen (HBsAg) carrier or who has resolved HBV infection. Therefore, the screening of patients before biological treatment and the application of a prophylactic treatment, particularly with respect to latent HBV infections, are recommended when necessary. This guideline covers pre-treatment screening and follow-up recommendations, if required, with respect to viral hepatitides in rheumatology patients who are planned to be given biological drugs. Although this guideline is prepared for biological disease-modifying antirheumatic drugs (DMARDs), it is recommended to be used also for target-oriented DMARDS and medium-high dose corticosteroids (>7.5 mg prednisolone/day equivalent). It should be considered that the reactivation risk is higher when more than one immunosuppressive drug is used.
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2016 |
---|---|
Erschienen: |
2016 |
Enthalten in: |
Zur Gesamtaufnahme - volume:3 |
---|---|
Enthalten in: |
European journal of rheumatology - 3(2016), 1 vom: 19. März, Seite 25-28 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Karadağ, Ömer [VerfasserIn] |
---|
Themen: |
Biologic drugs |
---|
Anmerkungen: |
Date Revised 01.10.2020 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
NLM265041570 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM265041570 | ||
003 | DE-627 | ||
005 | 20231224211421.0 | ||
007 | tu | ||
008 | 231224s2016 xx ||||| 00| ||eng c | ||
028 | 5 | 2 | |a pubmed24n0883.xml |
035 | |a (DE-627)NLM265041570 | ||
035 | |a (NLM)27708965 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Karadağ, Ömer |e verfasserin |4 aut | |
245 | 1 | 0 | |a Viral hepatitis screening guideline before biological drug use in rheumatic patients |
264 | 1 | |c 2016 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a Date Revised 01.10.2020 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a Biological drugs (tumor necrosis factor inhibitors, rituximab, tocilizumab, abatacept, and tofacitinib) are important treatment alternatives in rheumatology, particularly for resistant patients. However, they may cause hepatitis B virus (HBV) and hepatitis C virus (HCV) reactivation; for instance, HBV reactivation may occur in a patient who is an inactive hepatitis B surface antigen (HBsAg) carrier or who has resolved HBV infection. Therefore, the screening of patients before biological treatment and the application of a prophylactic treatment, particularly with respect to latent HBV infections, are recommended when necessary. This guideline covers pre-treatment screening and follow-up recommendations, if required, with respect to viral hepatitides in rheumatology patients who are planned to be given biological drugs. Although this guideline is prepared for biological disease-modifying antirheumatic drugs (DMARDs), it is recommended to be used also for target-oriented DMARDS and medium-high dose corticosteroids (>7.5 mg prednisolone/day equivalent). It should be considered that the reactivation risk is higher when more than one immunosuppressive drug is used | ||
650 | 4 | |a Review | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Viral hepatitis | |
650 | 4 | |a biologic drugs | |
650 | 4 | |a rheumatic patients | |
700 | 1 | |a Kaşifoğlu, Timuçin |e verfasserin |4 aut | |
700 | 1 | |a Özer, Birol |e verfasserin |4 aut | |
700 | 1 | |a Kaymakoğlu, Sabahattin |e verfasserin |4 aut | |
700 | 1 | |a Kuş, Yeşim |e verfasserin |4 aut | |
700 | 1 | |a İnanç, Murat |e verfasserin |4 aut | |
700 | 1 | |a Keser, Gökhan |e verfasserin |4 aut | |
700 | 1 | |a Kiraz, Sedat |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t European journal of rheumatology |d 2014 |g 3(2016), 1 vom: 19. März, Seite 25-28 |w (DE-627)NLM265040523 |x 2147-9720 |7 nnns |
773 | 1 | 8 | |g volume:3 |g year:2016 |g number:1 |g day:19 |g month:03 |g pages:25-28 |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 3 |j 2016 |e 1 |b 19 |c 03 |h 25-28 |